CSL News: New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated wit - 11th Oct 2023, 11:30pm

[annb0t]

Data evaluating the impact of cell-based quadrivalent influenza vaccines suggests an additional 31%–39% of influenza cases may have been prevented among persons 0–64 years of age during the 2017-2020 U.S. flu seasons.1 Vaccination of children 6 months to 17 years of age with cell-based quadrivalent influenza vaccines would be cost-effective in >95% of simulations, compared to traditional egg-based vaccines based on modeling data from 2011/12 and 2017/18 U.S. flu seasons.2 Influenza vac...

>>> Read more: New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines